301 related articles for article (PubMed ID: 31756985)
21. Vitamin D Receptor Controls Cell Stemness in Acute Myeloid Leukemia and in Normal Bone Marrow.
Paubelle E; Zylbersztejn F; Maciel TT; Carvalho C; Mupo A; Cheok M; Lieben L; Sujobert P; Decroocq J; Yokoyama A; Asnafi V; Macintyre E; Tamburini J; Bardet V; Castaigne S; Preudhomme C; Dombret H; Carmeliet G; Bouscary D; Ginzburg YZ; de Thé H; Benhamou M; Monteiro RC; Vassiliou GS; Hermine O; Moura IC
Cell Rep; 2020 Jan; 30(3):739-754.e4. PubMed ID: 31968250
[TBL] [Abstract][Full Text] [Related]
22. Leukemic stem cell signatures identify novel therapeutics targeting acute myeloid leukemia.
Laverdière I; Boileau M; Neumann AL; Frison H; Mitchell A; Ng SWK; Wang JCY; Minden MD; Eppert K
Blood Cancer J; 2018 Jun; 8(6):52. PubMed ID: 29921955
[TBL] [Abstract][Full Text] [Related]
23. The effect of cantharidins on leukemic stem cells.
Dorn DC; Kou CA; Png KJ; Moore MA
Int J Cancer; 2009 May; 124(9):2186-99. PubMed ID: 19123473
[TBL] [Abstract][Full Text] [Related]
24. HDAC8 Inhibition Specifically Targets Inv(16) Acute Myeloid Leukemic Stem Cells by Restoring p53 Acetylation.
Qi J; Singh S; Hua WK; Cai Q; Chao SW; Li L; Liu H; Ho Y; McDonald T; Lin A; Marcucci G; Bhatia R; Huang WJ; Chang CI; Kuo YH
Cell Stem Cell; 2015 Nov; 17(5):597-610. PubMed ID: 26387755
[TBL] [Abstract][Full Text] [Related]
25. GPR84 sustains aberrant β-catenin signaling in leukemic stem cells for maintenance of MLL leukemogenesis.
Dietrich PA; Yang C; Leung HH; Lynch JR; Gonzales E; Liu B; Haber M; Norris MD; Wang J; Wang JY
Blood; 2014 Nov; 124(22):3284-94. PubMed ID: 25293777
[TBL] [Abstract][Full Text] [Related]
26. Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and ex Vivo Patient Derived Therapeutic Efficacy.
Guo J; Russell EG; Darcy R; Cotter TG; McKenna SL; Cahill MR; O'Driscoll CM
Mol Pharm; 2017 Mar; 14(3):940-952. PubMed ID: 28146632
[TBL] [Abstract][Full Text] [Related]
27. Binding and functional pharmacological characteristics of gepant-type antagonists in rat brain and mesenteric arteries.
Sheykhzade M; Amandi N; Pla MV; Abdolalizadeh B; Sams A; Warfvinge K; Edvinsson L; Pickering DS
Vascul Pharmacol; 2017 Mar; 90():36-43. PubMed ID: 28192258
[TBL] [Abstract][Full Text] [Related]
28. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in
Jiang X; Mak PY; Mu H; Tao W; Mak DH; Kornblau S; Zhang Q; Ruvolo P; Burks JK; Zhang W; McQueen T; Pan R; Zhou H; Konopleva M; Cortes J; Liu Q; Andreeff M; Carter BZ
Clin Cancer Res; 2018 May; 24(10):2417-2429. PubMed ID: 29463558
[No Abstract] [Full Text] [Related]
29. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
30. Targeted inhibition of ULK1 enhances daunorubicin sensitivity in acute myeloid leukemia.
Qiu L; Zhou G; Cao S
Life Sci; 2020 Feb; 243():117234. PubMed ID: 31887299
[TBL] [Abstract][Full Text] [Related]
31. Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy.
Maganti HB; Jrade H; Cafariello C; Manias Rothberg JL; Porter CJ; Yockell-Lelièvre J; Battaion HL; Khan ST; Howard JP; Li Y; Grzybowski AT; Sabri E; Ruthenburg AJ; Dilworth FJ; Perkins TJ; Sabloff M; Ito CY; Stanford WL
Cancer Discov; 2018 Nov; 8(11):1376-1389. PubMed ID: 30115703
[TBL] [Abstract][Full Text] [Related]
32. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
33. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
[No Abstract] [Full Text] [Related]
34. High affinity and covalent-binding microtubule stabilizing agents show activity in chemotherapy-resistant acute myeloid leukemia cells.
Pera B; Calvo-Vidal MN; Ambati S; Jordi M; Kahn A; Díaz JF; Fang W; Altmann KH; Cerchietti L; Moore MAS
Cancer Lett; 2015 Nov; 368(1):97-104. PubMed ID: 26277539
[TBL] [Abstract][Full Text] [Related]
35. Single-Cell Gene Expression Analyses Reveal Distinct Self-Renewing and Proliferating Subsets in the Leukemia Stem Cell Compartment in Acute Myeloid Leukemia.
Sachs K; Sarver AL; Noble-Orcutt KE; LaRue RS; Antony ML; Chang D; Lee Y; Navis CM; Hillesheim AL; Nykaza IR; Ha NA; Hansen CJ; Karadag FK; Bergerson RJ; Verneris MR; Meredith MM; Schomaker ML; Linden MA; Myers CL; Largaespada DA; Sachs Z
Cancer Res; 2020 Feb; 80(3):458-470. PubMed ID: 31784425
[TBL] [Abstract][Full Text] [Related]
36. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia.
Ho MM; Hogge DE; Ling V
Exp Hematol; 2008 Apr; 36(4):433-42. PubMed ID: 18249061
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
38. Dual inhibition of EZH1/2 breaks the quiescence of leukemia stem cells in acute myeloid leukemia.
Fujita S; Honma D; Adachi N; Araki K; Takamatsu E; Katsumoto T; Yamagata K; Akashi K; Aoyama K; Iwama A; Kitabayashi I
Leukemia; 2018 Apr; 32(4):855-864. PubMed ID: 28951561
[TBL] [Abstract][Full Text] [Related]
39. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2.
Xu B; Wang S; Li R; Chen K; He L; Deng M; Kannappan V; Zha J; Dong H; Wang W
Cell Death Dis; 2017 May; 8(5):e2797. PubMed ID: 28518151
[TBL] [Abstract][Full Text] [Related]
40. Differences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis.
Feder K; Edmaier-Schröger K; Rawat VPS; Kirsten N; Metzeler K; Kraus JM; Döhner K; Döhner H; Kestler HA; Feuring-Buske M; Buske C
Leukemia; 2020 Apr; 34(4):1027-1037. PubMed ID: 31758089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
